Ken Olivier, Ph.D.
VP of Non-clinical Development
“Of the 20+ companies I have supported, TScan has the best attiTUDE and expertise to address patient’s needs with a highly engineered potential cure to improve the quality of their lives.”
Kenneth J. Olivier Jr., PhD, has been developing drugs for over 18 years and is currently serving as vice president of development at TScan Therapeutics, Inc. Dr. Olivier’s work experience includes biotechnology and pharmaceutical companies developing small molecule drugs, biologics, diagnostics, antibody drug conjugates, antibody directed nanotherapies, gene (AAV, LV vectors) and cell based therapies (TAA and TCR) for indications in cardiology, neurology, metabolic disease, neuromuscular disease, immunology, rare disease, infectious disease, fibrosis and oncology. Though his primary duties have been safety evaluations, Dr. Olivier has held the roles of project leader, head of project management, head of regulatory, head of pharmacokinetics, head of bioanalytical development, validation and sample analysis and head of nonclinical supporting multiple INDs, IMPDs, CTAs, NDAs, BLAs, PLEs and IDEs. Dr. Olivier obtained a BS in Toxicology from the University of Louisiana at Monroe and a PhD in Veterinary Biomedical Sciences from Oklahoma State University.
With a drive for continuous improvement and learning, Dr. Olivier is an adjunct faculty member at Oklahoma State University and has taught drug development courses at Harvard, MIT and through the American College of Toxicology, for which he is currently serving on the Editorial Board (International Journal of Toxicology) and formerly as an elected Council Member. Dr. Olivier has spent the past 15 years training CSOs, CEOs, CMOs, Project Team Leaders, Functional Heads and Team members on how to transition from discovery to development to market approval (within private and public companies), covering all topics related to drug development.